Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
Get Alerts KRYS Hot Sheet
Join SI Premium – FREE
PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:20 pm PT and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 2:20 pm PT on Tuesday, May 14, 2024 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACTInvestors and Media: Stéphane PaquetteKrystal Biotech[email protected]
Source: Krystal Biotech, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HYPERLIQUID Draws Fresh Attention as IceBull Enters the Next Crypto to Explode Race With Stage 1 Still Live
- Nick Good Earns RealTrends Verified #1 Rank in Plano, Texas
- JOINT STATEMENT OF OCEAN AND LUKE DASHJR
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share